Atlas Trials

A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma

Clinical trial NCT07604285 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07604285
Sponsor
Myosin Therapeutics Inc.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Glioblastoma
Start date
2026-07-01
Primary completion
2027-03-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.